![Amniotics]

Today is the last day of trading in Amniotics's warrants of series TO1

Today, 17 May 2022, is the last day of trading for the warrants of series TO1 (the "warrants") which Amniotics AB (publ) ("Amniotics" or the "Company") issued in connection with the listing on Nasdaq First North Growth Market on July 6, 2021. One (1) warrant entitle the holder to subscribe for one (1) new share in Amniotics at a subscription price of SEK 23.50. Upon full exercise of all warrants, Amniotics will receive approximately SEK 34.4 million before issue costs. The exercise period for the warrants runs up to and including 19 May 2022.

Instructions on how to subscribe for shares in Amniotics through the exercise of the warrant can be found in the press release that Amniotics published on 5 May 2022.

Holders of warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before 19 May 2022 as different nominees have different processing times.

Holders of warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of warrants by filling in and submitting an application form for the exercise, so that the application form is received by the issuing agent, Nordic Issuing, no later than 19 May 2022. The application form is available on the Company's, the issuing agent's, and Redeye AB's respective websites (www.Amniotics.com, www.nordic-issuing se, www.redeye.se). Please note that payment for the new shares must be received by Nordic Issuing no later than 19 May 2022 in accordance with the instructions on the application form.

Please note that warrants that are not exercised on or before 19 May 2022 will expire without value. Holders who do not wish to exercise their warrants may sell them today, 17 May 2022, at the latest.

Advisers
Redeye AB acts as financial adviser and Nordic Issuing AB acts as the issuing agent in the transaction.

For further information, please contact:

Kåre Engkilde
CEO, Amniotics AB
Phone: +46 (0) 723 27 85 20
Email: ke@amniotics.com

Johny Humaloja
CFO, Amniotics AB
Phone: +46 (0) 735 0668 56
Email: jh@amniotics.com

Amniotics AB (publ) 559024-6558
Medicon Village,
Scheelevägen 2, 223 63 Lund, Sweden

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has it´s headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.

Learn more at www.amniotics.com.

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

Attachments

Today is the last day of trading in Amniotics's warrants of series TO1